IV thyroxin
Phase 3Small molecule
IV thyroxin is one of 38 small molecule programs targeting Asthma. It is currently in Phase 3.
2
Indications
5
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
175 competitors in Asthma
#DrugCompanyPhaseTrials
1IV thyroxin
RRambam Health Care Campus
Phase 3
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
DUPIXENT
RegeneronPreclinical
Atrovent
Boehringer IngelheimPreclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
Ozone
TTanta University
Preclinical
Biological Drug
UUniversitaire Ziekenhuizen KU Leuven
Preclinical
Guanidine Hydrochloride
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Rhinovirus
UUniversity of Virginia
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Heart Failure2 trials
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IV thyroxin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRambam Health Care Campus